Covishield Side Effects: Dr. Mukesh Maheshwari Urges Caution for Heart Patients – Consultation Before Medication Initiation
The year 2020 brought forth a global calamity that shook the entire world. India, too, witnessed numerous casualties due to the coronavirus pandemic. In an effort to combat the virus, the Indian government embarked on a mission to provide free vaccines.
Beginning with the administration of Covaxin, developed by Bharat Biotech, and subsequently introducing Covishield, manufactured by the British pharmaceutical company AstraZeneca, the vaccination drive targeted 70 to 80 percent of the nation’s population. Despite initial apprehensions among those who have received these doses, Dr. Mukesh Maheshwari, the Vice President of the Ahmedabad Medical Association, reassures that there is no need for alarm.
Understanding the Risks of Covishield: Potential Implications for Heart Attack and Brain Stroke
Dr. Mukesh Maheshwari highlighted concerns regarding the Covishield vaccine, which was developed by the collaboration of the British pharmaceutical company AstraZeneca and India’s Serum Institute.
Approximately 200 crore doses of Covishield were administered, following its approval by UK courts. However, post-vaccination, adverse effects have been reported. AstraZeneca has acknowledged the possibility of serious side effects, such as Thrombocytopenia Syndrome (TTS), characterized by blood clotting issues, particularly leading to thrombosis.
Consequently, individuals who have received this vaccine may face an increased risk of developing blood clots, potentially leading to heart attacks or brain strokes.
WHO Research on Covishield: A Call for Global Oversight
In light of recent concerns surrounding Covishield, it is imperative to conduct thorough research, particularly by esteemed global organizations such as the World Health Organization (WHO) and UNICEF. Following the acceptance of AstraZeneca’s vaccine, alarming reports have surfaced regarding the development of blood clots and cardiac complications in some individuals post-vaccination.
In response, it is strongly advised for individuals to seek immediate medical advice and proceed with medication only after consultation with a qualified physician. Dr. Mukesh Maheshwari, Vice President of the Ahmedabad Medical Association, underscores the necessity for caution in light of these developments.
While the company has obtained approval, it is essential to note that Covishield was not designed for regular use but rather for emergency situations. Typically, vaccines undergo a rigorous 8 to 10-year process for regular usage to ensure safety and efficacy. However, there is no need to panic. Yet, vigilance remains crucial.
Therefore, it is imperative for global health organizations such as WHO to conduct comprehensive research to ascertain the safety and efficacy of the Covishield vaccine.
